Fibrosis pathway mediators

"Fibrosis pathway mediators" refers to an array of molecular regulators, including growth factors (e.g. Transforming Growth Factor β, Platelet-Derived Growth Factors, Connective Tissue Growth Factor), cytokines (such as IL-10 family members), enzymes (proteases, kinases), and cell-surface receptors (e.g. GPCRs, receptor tyrosine kinases) driving the biological processes leading to tissue fibrosis[1][2][3][4][8]. These mediators orchestrate the activation of fibroblasts to myofibroblasts, regulate extracellular matrix production, and are implicated in inflammation, cell differentiation, and wound healing. Because fibrosis involves complex cross-talk among these pathways, individual mediators (such as TGF-β and CTGF) are considered actionable drug targets, while the broad category of "fibrosis pathway mediators" lacks specificity and is not a canonical or singular therapeutic entity.

Other names

Fibrotic mediatorsPro-fibrotic signaling proteinsFibrogenic pathway mediators

Inhibition of TGF-β signaling\nBlockade of growth factor receptors (e.g. PDGFR)\nModulation of cytokine and chemokine signaling\nInhibition of myofibroblast activation and ECM deposition[3][5][1][4]